New pill targets Hard-to-Treat cancers with rare TP53 mutation
Disease control
Recruiting now
This study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …
Phase: PHASE1, PHASE2 • Sponsor: Nutshell Therapeutics (Shanghai) Co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC